News Details

Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China

About Pfizer, Inc.
  • NYSE: $PFE
  • Notified: $38.20
  • 01:15 EDT

Price Chart